Portola Pharmaceuticals

Merck returns $50M anti-clotting drug betrixaban to Portola
bizjournals.com
Thu, 03/24/11 - 03:14 pm
Merck
betrixaban
Portola Pharmaceuticals
anti-clotting
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Sun Herald, MS
Sun, 12/5/10 - 12:16 pm
Portola Pharmaceuticals
non-Hodgkin's lymphoma
chronic lymphocytic leukemia
rheumatoid arthritis
JAK inhibitors
Syk inhibitors
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Seeking Alpha
Mon, 09/20/10 - 10:58 am
blood thinners
AstraZeneca
Bristol-Myers Squibb
Bayer
Eisai
Pfizer
Sanofi
Brilinta
Portola Pharmaceuticals
Boehringer Ingelheim
Portola, Merck anticoagulant shows strong response
Bizjournals.com
Mon, 03/15/10 - 04:18 pm
anticoagulants
Portola Pharmaceuticals
Merck
betrixaban
Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
BNET Pharma
Tue, 11/24/09 - 09:54 am
biotech
IPOs
Ironwood
Trius Therapeutics
Portola Pharmaceuticals
Pacific Biosciences
Regulus
Concert Pharmaceuticals
Macrogenics
Merck Strong in Cardiovasculars
Yahoo/Zacks.com
Sat, 07/11/09 - 08:43 am
Merck
Portola Pharmaceuticals
Schering Plough
Zetia
Vernakalant
Cardiome
Vytorin
Merck Enters Licensing Agreement With Portola for Stroke Drug
Bloomberg
Thu, 07/9/09 - 08:32 am
Merck
stroke
licensing
Portola Pharmaceuticals
betrixaban
The 15 most promising biotech companies
Fierce Pharma
Mon, 06/29/09 - 03:41 pm
biotech
Achaogen
Agios Pharmaceuticals
Aileron
BioVex
Calistoga Pharmaceuticals
Clovis Oncology
Heptares Therapeutics
Ironwood
iZumi Bio
KaloBios
Pacific Biosciences
Portola Pharmaceuticals
Proteon Therapeutics
VaxInnate
Zafgen
Novartis buys rights for cardiovascular compound
Hays Pharma,UK
Thu, 02/12/09 - 07:26 am
Novartis
Portola Pharmaceuticals
Elinogrel

Pages